Published in final edited form as:

Best Pract Res Clin Rheumatol. 2009 October ; 23(5): 665–678. doi:10.1016/j.berh.2009.07.007.

Juvenile Dermatomyositis: New Developments in Pathogenesis, Assessment and Treatment

Lucy R Wedderburn, MD PhD¹ and Lisa G Rider, MD²

¹Rheumatology Unit, Institute of Child Health, University College London, UK

²Environmental Autoimmunity Group, Office of Clinical Research, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

Abstract

Juvenile dermatomyositis (JDM) is a rare, potentially life-threatening systemic autoimmune disease primarily affecting muscle and skin. Recent advances in the recognition, standardised assessment and treatment of JDM have been greatly facilitated by large collaborative research networks. Through these networks, a number of immunogenetic risk factors have now been defined, as well as a number of potential pathways identified in the aetio-pathogenesis of JDM. Myositis-associated and myositis-specific autoantibodies are helping to sub-phenotype JDM, defined by clinical features, outcomes and immunogenetic risk factors. Partially validated tools to assess disease activity and damage have assisted in standardising outcomes. Aggressive treatment approaches, including multiple initial therapies, as well as new drugs and biologic therapies for refractory disease, offer promise of improved outcomes and less corticosteroid-related toxicity.

Keywords

juvenile dermatomyositis (JDM); Idiopathic inflammatory myopathy (IIM); immunogenetics; myositis autoantibodies; outcome measures; therapy

1. Introduction

Juvenile dermatomyositis (JDM) is a rare, serious autoimmune condition of childhood involving a systemic small vessel vasculopathy, which typically affects skin and muscle, but can also involve the joints, gut, lung, heart, and other internal organs. JDM is the most common of the Idiopathic Inflammatory Myopathies (IIM) of childhood and therefore is the focus of this review. Other paediatric IIM, and also the parallel adult conditions, will be referred to for comparison with their common features, where appropriate. Increasing evidence suggests that early aggressive management of JDM improves outcome, while conversely, a long duration of untreated disease is associated with longer time to reach remission and higher rates of complications such as ongoing skin disease or osteoporosis [1,2]. Therefore, the recognition,

© 2009 Elsevier Ltd. All rights reserved.

Corresponding author: Dr Lucy R. Wedderburn, Rheumatology Unit, Institute of Child Health, UCL 30 Guilford Street, London WC1N 1EH, UK Tel : 44 207 905 2391 Fax : 44 207 813 8494 l.wedderburn@ich.ucl.ac.uk.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

prompt referral to specialist care, and early treatment, of patients with JDM are of paramount importance.

2. JDM: incidence and diagnostic criteria

The incidence of JDM is between 2 and 3 children per million per year, with some differences between ethnic groups [3,4]. JDM is more common in girls than boys, by a ratio of approximately 2.3:1 [4,5] although some reports suggest that this ratio may be lower in younger age groups [6]. The mean age of onset of JDM is just over 7 years; however a recent report of 286 patients showed that 25% of cases present when less than 4 years of age [7], and some specialists suggest that young age of onset is associated with poor prognosis.

Clinical features are central to the diagnosis of JDM, the most frequent being the characteristic heliotrope rash and Gottron's papules over the extensor surfaces, and proximal muscle weakness. A wide range of other features may be present early in the course of disease [8], making design of diagnostic criteria which are both comprehensive, yet not too complex or unwieldy, difficult. In a study from a UK Registry including data on 151 children, 81% of cases had one or more 'systemic' symptoms at presentation, which included fever, malaise anorexia, weight loss, irritability or abdominal pain [5]. At present the most widely used set of criteria remain those defined by Bohan and Peter in 1975 [9], which require the presence of one of the characteristic rashes, combined with three of the following features, for definite JDM: symmetric proximal muscle weakness, raised serum muscle enzymes (which may include creatine kinase (CK), transaminases, lactate dehydrogenase (LDH) and aldolase), abnormal findings on muscle biopsy and electromyography (EMG). The presence of the rash with two of these features make a diagnosis of probable JDM. These criteria, now over 30 years old, no longer reflect modern diagnostic investigation of suspected cases of JDM. Although magnetic resonance imaging (MRI) findings are not part of the Bohan and Peter criteria, MRI is now widely used to detect typical inflammatory changes in proximal muscles, and quantitation of such changes has been shown to correlate with disease activity [10]. In an international survey of 118 clinicians from 92 centres caring for children with JDM, routine use of EMG and muscle biopsy were found to be as low as 56% and 61% respectively [11], primarily due to the consideration that these are invasive procedures. Until recently there has been no standardised system for assessment of muscle biopsy tissue for JDM, resulting in the information obtained dependent on local expertise. A recent international consensus working group on JDM biopsy has proposed a score tool, which may improve routine assessment of JDM muscle biopsy tissue [12]. Muscle biopsy remains a critical investigation, especially in the absence of the characteristic rashes and where differential diagnoses such as genetic or metabolic myopathies are being considered.

A large international collaborative group, the International Myositis Assessment and Clinical Studies Group (IMACS) recently proposed that the Bohan and Peter criteria should be used for inclusion in therapeutic trials [13]. An international collaborative effort is now underway to revise criteria for the classification of IIM in both adults and children.
(<http://www.niehs.nih.gov/research/resources/collab/imacs/classificationcriteria.cfm>)

3. Aetiology and pathogenesis of JDM

While the aetiology of JDM remains unclear, the working hypothesis is that this involves environmental triggers, immune dysfunction, and specific tissue responses (in particular those of muscle, skin and small vessel endothelium), in genetically susceptible individuals. Recently there have been considerable advances in our knowledge of genetic risk factors for a number of autoimmune conditions. These are complex polygenic disorders, in which variation at many genetic loci may contribute to susceptibility. It is known that several genes confer risk for an 'autoimmune' phenotype as a whole [14]. Until recently the lack of large collections of genetic

material linked to carefully phenotyped myositis patients hampered progress in this area. However the past few years have seen enormous growth in multi-centre collections and registries [4,5,15,16], as well as the establishment of an international genetics consortium in myositis, MYOGEN.

The human leukocyte region (HLA), which lies within the major histocompatibility complex (MHC), is one of the most highly polymorphic regions of the human genome, carries alleles associated with increased risk for many autoimmune diseases, including JDM. Thus HLA-B*08, DRB1*0301, and DQA1*0501 are part of an extended ancestral haplotype that confers risk of myositis in both adults and children in Caucasians [17-20]. Recent work has shown that HLA-DPB1*0101 also confers independent risk of myositis in both adults and children, in particular serological subgroups [21], and that the DQA1*0301 allele is an additional risk factor for JDM [19]. Caucasian patients with JDM also have several protective alleles, including DQA1*0201, DQA1*0101, and DQA1*0102 [19], which are less frequent in affected patients than in healthy controls and may mechanistically contribute to disease development through binding of self-reactive antigens and the elimination of self-reactive T lymphocytes from the thymus. Several other polymorphic loci have been shown to be risk factors for JDM, including the pro inflammatory cytokine genes TNF α [16,22], IL-1 α and IL-1 β [16], the lymphocyte signalling gene PTPN22 [23] and phenotypes of the immunoglobulin heavy chain [24]. The TNF α variant known as TNF308A carries a higher risk of calcinosis and ulcerations [16,22], and in controls this genotype is associated with higher levels of TNF production [25]. The TNF308A effect may be independent of the HLA-DRB1 locus, but may be in part due to linkage disequilibrium with the HLA-B locus [26]. An IL-1 polymorphism confers additional risk for the development of calcinosis [16].

Environmental factors associated with onset of JDM have been infrequently studied. A high frequency of symptoms consistent with infection within a few months prior to onset, have been reported in large cohorts and one case-controlled study [7,27]. Searches for infectious agents, including parvovirus and enteroviruses, have been negative in case-controlled studies [28, 29]. Seasonality in birth distribution in certain subsets of disease, including Hispanic patients, those with a myositis autoantibody known as the p155/140 autoantibody, and those with the HLA-DRB1*0301 risk allele, suggest a role for perinatal environmental factors in the onset of illness later in childhood [30]. Anecdotal reports of JDM onset after exposure to drugs, biologic therapies, vaccines, and ultraviolet light also exist [31]. Additional case-controlled studies, including examination of non-infectious environmental factors, are needed to identify environmental risk factors for JDM.

Autoantibodies are common in JDM, and can be divided into two categories: myositis specific antibodies (MSA), typically directed at cytoplasmic or nuclear components involved in protein synthesis (such as the aminoacyl-tRNA synthetases) and nuclear transcription, which are relatively specific for myositis or subtypes of disease; and myositis associated antibodies (MAA) which are also found in other autoimmune conditions and overlap syndromes (Table 1). Approximately 70% of children with JDM have one or more detectable MSA or MAA if full serological testing is used [20,32] although the frequency of different antibodies differs in different ethnicities [24]. Clinical associations of such autoantibodies parallel those seen in adult disease in some cases, such as the association of anti PM-Scl with sclerodermatous features, anti-Jo-1 with interstitial lung disease and other extra-muscular features, anti-SRP with severe polymyositis, and anti-Mi-2 with classic DM rashes and milder disease [20,31, 33]. From several studies in myositis, it has become clear that certain genetic risk alleles are associated with specific autoantibody phenotypes, and that these associations hold true across age groups in both adults and children. For example, the HLA-DRB1*03-DQA1*05-DQB1*02 haplotype is increased in patients with anti-PM-Scl autoantibody, the HLA-DRB1*04-DQA1*03-DQB1*03 haplotype with anti-U1-RNP autoantibody [20] and HLA-B*08-

DRB1*0301-DQA1*0501-DPB1*0101 (as part of the ancestral haplotype) are associated with anti-Jo-1 autoantibody [21,34].

In addition to the well-characterised autoantibodies, several new specificities have recently been defined in JDM. An autoantibody to a 155kDa protein, in most cases associated with a second weaker 140kDa band, now known as anti-p155/140, has been shown to be present in sera of 23-29% of JDM cases and to associate with risk of more severe skin involvement and generalized lipodystrophy [35-37]. In adults this anti-p155/140 autoantibody is associated with cancer-associated dermatomyositis, but no such link has been seen in JDM. A second novel autoantibody known as anti-p140 has been demonstrated in sera of 23% of JDM patients and is associated with a higher risk of calcinosis than patients who do not have anti-p140 autoantibody [38]. It is also of note that in a study of autoantibodies in 114 JDM cases, many cases were ANA positive yet who had no identifiable known autoantibody, suggesting that further novel antibodies in JDM await identification [20].

Genetic variants and autoantibodies, or a combination of both, may prove useful to generate predictors of clinical phenotypes or disease course in juvenile myositis. In addition some evidence has suggested potential roles for autoantibodies in the pathogenesis of myositis. Autoantigens to which MSA are directed may be upregulated in inflammatory myopathy muscle biopsies, particularly in regenerating myoblasts [39]. Some of these same autoantigens are themselves chemoattractant to immune cells [40] and interestingly, a study in adult myositis recently showed that immune complexes of anti-Jo-1 or anti-Ro 52/anti-Ro60 autoantibodies can induce type I interferon production [41], a cytokine already linked with JDM pathogenesis [42,43].

In attempts to understand underlying mechanisms of muscle weakness and tissue damage in myositis, analysis of muscle biopsy tissue has been important. Typical features of JDM biopsies include inflammatory changes, classically lymphocytic infiltration in a perivascular pattern, and/or myeloid cell infiltration in a scattered distribution, muscle fibre MHC class I protein over expression, endothelial and small vessel abnormalities (with complement C5-9, and/or immunoglobulin deposition), muscle fibre regeneration or necrosis, and fibre atrophy. The consensus group on JDM biopsy proposed a system by which to score features and severity on JDM biopsy, using four domains: inflammatory, vascular/endothelial changes, muscle fibre abnormalities, including staining for MHC class I over expression, and connective tissue changes [12]. Prospective testing of the power of this tool to predict disease features is underway, while a retrospective study using a related scoring system suggested that arteriopathic changes and capillary loss correlated with chronic disease course [44].

Typical changes on JDM biopsy of endothelial dysfunction and depletion of capillaries, combined with clinical features suggestive of small vessel angiopathy such as gut involvement and perforation, led to the proposal that JDM is a small vessel vasculopathy [45]. Antibody deposition and complement activation likely contribute to endothelial dysfunction and damage, in both muscle and involved skin. The endothelium within affected muscle itself produces immune mediators such as IL-1 and other cytokines [46], as well as enhances inflammation via upregulated adhesion molecules ICAM-1 and VCAM [47]. Activated endothelium is also an important binding site for chemokines, which then attract inflammatory cells, and also influence blood vessel physiology and angiogenesis. JDM muscle shows an excess of angiostatic chemokines (so called ELR-chemokines) such as IP-10 [CXCL10] which may contribute to endothelial damage and vasculopathy [48], and a study using gene expression profiling indicated dysregulation of both angiogenesis and angiostasis in JDM [49]. Inflammatory cells (T and B lymphocytes, dendritic cells and macrophages) are important sources of cytokines (including TNF α , IL-1) and chemokines within the muscle. There is mounting evidence for an important role for type I interferons in both JDM and adult DM

pathology [42,50], for which a major source is thought to be activated dendritic cells (DC), in particular the plasmacytoid DC which are present within the muscle [51]. Plasmacytoid DC also secrete chemokines which may contribute to lymphocytic aggregates, typically perivascular, that have been suggested to associate with a more severe disease course [52]. In addition to inflammatory cells originating from the child, there is evidence that cells of maternal origin are also present in the peripheral blood and muscle inflammatory infiltrates of JDM patients (so called microchimerism). Microchimeric cells are more common in children with JDM than their healthy siblings and may contribute to a 'graft-versus-host' – like process in several autoimmune conditions [53].

Many of the cytokines demonstrated to play a role in JDM, in particular interferons and TNF α , would contribute to the upregulation of class I MHC proteins on muscle fibres, a change that frequently occurs early in disease, when the muscle architecture is otherwise relatively unremarkable, and as such a useful addition to pathological analysis [54]. It is not clear how alteration of MHC class I affects function although evidence suggests that it may induce ER stress in muscle fibres. However, in a transgenic model where self-MHC is over expressed selectively in skeletal muscle, mice become weak and develop autoantibodies which mimic human MSA [55]. In muscle fibres isolated from this model, the muscle is already weak as early as 2 weeks after MHC overexpression [56]. A recent adaptation of this model in very young mice, designed to mimic JDM, demonstrated that young skeletal muscle is particularly vulnerable to the insult afforded by class I MHC overexpression [57].

4. New approaches to the assessment of JDM

Through international collaboration among myositis experts (IMACS) and paediatric rheumatologists (the Paediatric Rheumatology International Trials Organization, PRINTO), two parallel processes have been used to develop core set measures for JDM. IMACS and PRINTO, despite some differences in their approaches, developed core set measures of disease activity for JDM that are remarkably similar and include measurement of global activity, muscle strength, and physical function. In the case of IMACS, extra-muscular activity and laboratory enzymes are also included in the IMACS core set, whereas in the PRINTO core set, a global activity assessment tool and health-related quality of life measure are included instead [58,59]. To derive the core set of activity measures, IMACS reviewed data on the performance and validity of various measures in studies and trials of treatment-refractory patients, followed by a consensus approach that combined both nominal group technique (NGT) and a Delphi process. A consideration in the IMACS process was the availability and applicability of these measures to both juvenile and adult myositis. PRINTO, in contrast, undertook a consensus approach first on which measures to include in a provisional core set, followed by prospective validation in a multi-center study of recent-onset JDM patients, examining each measure's responsiveness and, in some cases, their construct validity, internal consistency, and discriminant validity [60]. The main change to the final PRINTO core set was a deletion of serum muscle enzymes, due a lower responsiveness and a decrease in internal consistency with inclusion of serum CK; nevertheless, reporting of serum muscle enzymes is still recommended.

IMACS subsequently developed a composite clinical endpoint for therapeutic trials that combines the core set measures, based on consensus ratings of improvement in paper patient profiles, the performance characteristics of various definitions of improvement, and consensus formation using NGT based on their face validity [61]. The top candidate definition of improvement for JDM requires improvement of at least 20% in 3 of 6 core set measures, with no more than 2 measures allowed to worsen (which cannot be muscle strength). PRINTO has preliminarily confirmed this approach in a separate consensus process, with their top candidate definition of improvement requiring 20% improvement in at least three core set measures, allowing for no more than one to worsen, which cannot be the Childhood Myositis Assessment

Scale (CMAS) [60,62,63]. The differences in these definitions of improvement may relate to differences in responsiveness between a recent-onset vs. refractory JDM populations, from which these outcome measures were derived. These definitions of improvement are being prospectively tested and validated in a number of therapeutic trials in both juvenile and adult myositis, and further refinement of these is anticipated.

Several tools for assessment of skin disease in JDM have been developed and partially validated. The Cutaneous Assessment Tool (CAT) was developed for assessment of skin activity and damage in juvenile and adult myositis, by assessing activity in 10 lesions, damage in 4 lesions and a combination of activity and damage in 7 lesions, using an *a priori* weighting scale to determine severity in each lesion. This tool has been partially validated in a large JDM population and demonstrated good rater-reliability, content and construct validity, and responsiveness [64,65]. An abbreviated method of scoring this tool performs similarly to the longer instrument [66]. An online photoessay of skin involvement in the IIM is now available, and is of educational value in improving recognition of the spectrum of cutaneous disease associated with JDM [67]. The Disease activity Score (DAS) for JDM also includes assessment of skin involvement and distribution, has good reliability and is detailed in the assessment of vasculopathic features of skin disease, with a moderate correlation with periungual nailfold capillary changes [68,69]. Persistent skin rashes and nailfold capillary abnormalities are thought to indicate continuing active disease, and therefore their assessment is of great importance. Persistent nailfold capillary changes are associated with a chronic ('non-unicyclic') disease course [2]; in a small pharmacokinetic study, poor oral absorption of prednisolone correlated with end row loss of nailfold capillaries, suggestive of gut vasculopathy [70]. Several tools to assess skin disease in adult DM have also been proposed including the Dermatomyositis Skin Severity Index (DSSI) modified from the Psoriasis Area and Assessment Index (PASI) [71] and the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) [72]. Calcinosis, also felt by some specialists to indicate continuing disease activity is also an important cause of morbidity in JDM and therefore important to assess.

In terms of health-related quality of life, the Child Health Questionnaire (CHQ) has been examined in a large multi-center cohort by PRINTO, comparing physical and psychosocial components to healthy children [73]. Physical dysfunction scores on the CHQ most related to functional disability, parent's global assessment of well-being and ALT levels, while psychosocial well-being was most strongly associated with muscle strength and physical dysfunction.

The Myositis Damage Index is a modification of the Systemic Lupus International Collaborative Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index with the intention of comprehensively assessing the extent of damage in different organ systems and the severity of damage using a series of visual analog scales. Preliminary validation studies of the Myositis Damage Index in two large referral populations of juvenile myositis patients suggest that the majority of patients develop damage after several years of illness. Cutaneous scarring or atrophy was present in 30-40% of patients, joint contractures in 17-30%, calcinosis in 22-26%, persistent muscle dysfunction or weakness in 11-30%, and persistent dysphagia and dysphonia in 5 - 20% of patients in these cohorts, with an average of 2-6.8 years of follow-up from diagnosis [74,75]. In a recent report of 67 JDM patients who were followed into adulthood (median time from diagnosis 16.8 years), a high number of individuals still had high disease activity and damage scores, with active disease present (defined as DAS>3) in 61 % patients and Myositis Damage Index scores >1 in 90% [76]. However, this cohort would have received initial treatment on average 16 years ago when regimes were very different from current practice, and thus may not be reflective of the current JDM disease course.

Complications associated with JDM require specialised investigation. Many of these may be present at presentation or early in disease. Thus, severe features such as speech and swallowing changes require assessment by video-fluoroscopy [77], and lung CT scanning is required where pulmonary involvement is suspected. While generalized and partial lipodystrophy are seen as a complication of JDM that is associated with insulin resistance and hyperlipidemia [37], JDM patients without lipodystrophy also have a number of risk factors for later development of cardiovascular disease, such as frequent insulin resistance, hypertriglyceridemia, and the metabolic syndrome, including elevated body mass index and systolic blood pressure [78]. Insulin resistance correlated with thigh muscle atrophy, pro-inflammatory peripheral blood cytokines, and a family history of diabetes, but not with corticosteroid dose.

In the assessment of individual patients, serum levels of muscle enzymes may be helpful in determining ongoing active disease, but may also be normal or near normal, particularly with longer disease duration, and are often not revealing of active disease in organ systems outside the muscles. MRI at selected therapeutic junctures can be helpful to visualize activity outside of the muscles in the skin, subcutaneous tissue, or myofascia, which often does not correlate with muscle activity [79]. In order to better determine occult disease activity, a number of immunologic biomarkers appear promising, including phenotypes of peripheral blood mononuclear cells assessed by flow cytometry, measures of endothelial cell activation, and macrophage activation markers, including neopterin and quinolinic acid [80]. Newer markers including IFN α , and downstream targets of IFN α , or IL-17- and IFN γ -regulated genes, are all under investigation, and may prove to be sensitive markers of disease activity [50,81].

5. Evolving Treatment Paradigms

The mainstay of treatment for JDM remains high dose daily oral corticosteroid therapy, along with adjunctive steroid-sparing immunosuppressive therapies, which are used to treat disease activity, prevent mortality, and attempt to reduce long-term disability and calcinosis. Several reviews on the medical treatment of JDM provide detailed information on the uncontrolled retrospective reports and open-label prospective case series that have led to the treatment paradigm currently most widely used (Table 3) [31,82]. Initial drug treatment can be safely combined with early physical therapy, and a study using MRI pre- and post- exercise showed no evidence of muscle damage in children with JDM who underwent an exercise programme [83]. Emerging data, albeit open-label and based on comparison to a historic reference group, suggests that introduction of agents beyond oral corticosteroids as part of the initial therapy, including methotrexate and pulses of intravenous methylprednisolone (ivMP), and with additional therapy for inadequate responders, may shorten the course of illness, reduce calcinosis, reduce the likelihood of flare later in the illness course, and increase the chance of remission [84,85]. Early introduction of methotrexate (preferably given subcutaneously), alone or in conjunction with additional agents, may also be associated with reduced corticosteroid toxicity, including less weight gain, better growth velocity in the first year of treatment and reduced cataract formation, with an overall reduction in the duration and cumulative dose of corticosteroids [86]. IvMP (10 - 30 mg/kg/dose, maximum 1 gram) is also often used as part of first line therapy for JDM, with a goal of obtaining more rapid control of symptoms and reducing the toxicity associated with high-dose daily oral corticosteroids. The bioavailability of ivMP may be better than that of oral prednisone, particularly in patients with vasculopathy evidenced by reduced periungual nailfold capillary density [70]. A comparison of high dose corticosteroid therapy (ivMP 30 mg/kg/day or oral prednisone 5–30 mg/kg/day at diagnosis) compared to standard dose therapy (1–2 mg/kg/day daily oral prednisone) in a matched propensity score analysis adjusted for differences in illness severity and factors that determined treatment revealed no difference in outcome at 36 months, except the group treated initially with high dose intravenous therapy had higher levels of serum muscle enzymes [87].

Limitations of this analysis include that the sickest patients were treated with high dose ivMP

and excluded from analysis, and the propensity score analysis may not be adjusting for all of the factors that determined the initial selection of therapy, nor for therapies used after the initial treatment period.

Additional studies are in progress that may help guide clinicians on choice of initial therapy. PRINTO is currently conducting a randomized controlled trial to compare prednisone alone vs. prednisone in combination with methotrexate vs. prednisone in combination with cyclosporine as initial treatments for JDM (<http://www.printo.it/>). CARRA (Childhood Arthritis and Research Alliance based in North America), is developing consensus protocols for initial therapy of patients with moderate to severe JDM, that include combinations of prednisone, methotrexate, ivMP, with or without intravenous gammaglobulin (IVIG). In a number of open label studies, both retrospective and prospective, IVIG appears beneficial for JDM patients with refractory disease, resulting in decreases in skin and muscle activity and reduction in corticosteroid dosage, and is thought to be particularly helpful in patients with rapidly progressing disease, including dysphagia [31].

For patients with severe, refractory or corticosteroid-dependent disease, combinations of second line therapies or the addition of newer therapies are now frequently used. An open label study of iv monthly pulse cyclophosphamide administered to severe or treatment-refractory JDM patients demonstrated significant improvements in core set myositis activity measures (including muscle strength, function, extramuscular activity, enzymes and global activity) in 10 of 12 patients after 6 months [88]. Many of these patients notably had severe complications, including severe weakness, dysphagia, skin or gastrointestinal ulcerations, or central nervous system disease, that improved after the initiation of therapy. Complications of therapy included transient lymphopenia, herpes zoster, and alopecia. Anecdotal open-label reports, primarily in adult patients, support the use of mycophenolate mofetil for patients with severe disease, with improvement in strength, skin disease, muscle enzymes and an ability to reduce corticosteroid dose in the majority of patients [89]. Side effects in adult patients have included B-cell lymphoma, elevated hepatic enzymes and urinary tract symptoms, which resolved upon discontinuation of the drug. Seven treatment-refractory JDM patients improved in their skin and muscle Disease Activity Scores after receiving mycophenolate mofetil in an open label study. The major side effect was upper respiratory infections [90]. Use of oral tacrolimus receives some support from open label studies in adult IIM patients with treatment-refractory disease, the majority of whom improved [91]. In three patients with refractory JDM treated with tacrolimus, all improved their skin disease, global disease activity, physical function and were able to reduce corticosteroid therapy, and the medication was well-tolerated [92].

Biologic therapies are beginning to emerge for the treatment of myositis, supported to date primarily by open-label studies. Anecdotal case series and small open label trials suggest favorable responses to rituximab, a monoclonal antibody directed against B lymphocytes, in patients with severe, refractory disease, with a high frequency of response overall. In the first publication piloting rituximab in 7 refractory adult DM patients, all patients had a response commencing 4-12 weeks after the infusions that paralleled depletion of peripheral blood B lymphocytes (4 weekly infusions of 100 mg/m² or 375 mg/m²), with a maximal response at 12-36 weeks, and duration of effect lasting 24 to more than 52 weeks, often, but not always, paralleling the return of circulating B cells [93]. In four patients with refractory JDM, 3 achieved marked clinical responses and 1 experienced disease worsening [94]. In one study of refractory adult DM, little improvement in skin disease was noted [95]. The results of a large randomized controlled trial of rituximab in JDM and adult DM/PM (the Rituximab in Myositis study, RIM), which utilizes a randomized placebo-phase design, are anticipated. While infusion-related adverse events are most frequent, rare serious adverse events reported following rituximab treatment include infections, cardiotoxicity, progressive multifocal leukoencephalopathy, and intestinal perforation [96].

Responses to the anti-tumour necrosis factor alpha agents in the IIM have been mixed. In a series of 5 severe JDM cases treated with infliximab (3 mg/kg), all five improved after 8-30 months of infliximab, measured by improvement in core set measures, and in some cases in calcinosis, with no serious side effects reported [97]. An open-label study of etanercept in 10 treatment-refractory JDM patients demonstrated minimal improvement in muscle and no improvement in skin disease activity [98]. Responses to infliximab and etanercept have varied in adult DM/PM, with disease progression in some patients [99].

Newly available biologic therapies that appear promising in the treatment of inclusion body myositis or other immune-mediated diseases, such as CAMPATH-1H or a monoclonal antibody directed against IFN α , have not undergone formal testing in patients with juvenile myositis. Stem cell transplantation has been successfully used in a few patients with severe, refractory JDM [100] and is suggested as a final option for severe unremitting disease.

Practice points

1. The optimal recognition, detailed full assessment, and treatment, of children with JDM requires specialist, multi disciplinary teams, working in centres with experience with this group of rare and serious conditions.
2. Standardised approaches to assess JDM disease activity include a combination of measures to assess overall disease activity and damage, muscle weakness, functional disability, laboratory findings and extra-muscular activity, including the skin.
3. Although controlled evidence is frequently lacking for treatment in JDM, a number of studies confirm the value of aggressive treatment, with the aim to induce stable remission early, and thereby reduce steroid use and prevent disability and complications.
4. New and combined treatment regimes, including new disease modifying agents and biological therapies, are now in use for refractory JDM in many centres.
5. New insights into pathogenesis, myositis associated autoantibodies and genetic risk factors are generating novel ways to assess patients with JDM, and are likely to provide predictive biomarkers that may aid in the diagnosis or ongoing assessment of disease activity.

Research Agenda

1. New criteria based on clinical features and commonly used tests are needed to better diagnose and classify patients with JDM and other idiopathic inflammatory myopathies.
2. Whole genome scanning approaches using large multi-centre collections of detailed clinical data and biological samples should enable the identification of a number of new genetic risk factors for JDM and possibly genetic severity factors.
3. Several new autoantibodies have recently been identified as being common in JDM and may associate with risk of specific clinical features, outcomes and even pathogenesis.
4. Recent data implicating new mechanisms of pathogenesis in JDM, such as type I interferons or upregulation of Class I MHC may provide novel therapeutic targets.

5. Refinements in the combinations of core set measures to determine clinically significant improvement, as well as criteria for worsening or flare of disease, will aide in the assessment of novel therapies.

Summary

While the causes of JDM remain elusive, recent insights into genetics, autoantibodies, immune attack mechanisms and muscle response to injury all suggest mechanistic pathways which contribute to the pathology of JDM, both within muscle and also in other affected tissues. The standardised assessment of disease activity and damage in JDM has also led to the testing of new therapeutic agents. An initially aggressive approach with combination therapies as part of the early therapy of JDM may result in better long-term outcomes, including the possibility of less calcinosis, fewer corticosteroid side effects and a higher frequency of inactive disease, although these findings need to be confirmed in controlled studies and with long-term follow-up data. A number of disease-modifying drugs and new biologic therapies are emerging as therapeutic options for patients with refractory disease. The challenge now is to translate research findings on new aspects of pathogenesis into novel therapeutic strategies for those children who do not respond well to conventional management.

Acknowledgments

We thank Drs. Kathleen Coyle, Frederick Miller and Clarissa Pilkington for critical reading of the manuscript. We thank Dr Harsha Gunawardena for valuable advice on MSA and MAAs.

Acknowledgements of grant funding This work was supported in part by grants from the Wellcome Trust UK, Action Medical Research UK, the UK Myositis Support Group and the intramural research program of the National Institute of Environmental Health Sciences, National Institutes of Health.

References

10 key references are asterisked.

1. Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. *Arthritis Rheum* 2008;58:3585–92. [PubMed: 18975314]
2. Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, et al. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. *Arthritis Rheum* 2008;58:571–6. [PubMed: 18240225]
3. Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nationwide study. *Br J Rheumatol* 1995;34:732–6. [PubMed: 7551657]
4. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. *Arthritis Rheum* 2003;49:300–305. [PubMed: 12794783]
5. McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr. *Rheumatology* 2006;45:1255–60. [PubMed: 16567354]
6. Wedderburn LR, Li CK. Paediatric idiopathic inflammatory muscle disease. *Best Pract Res Clin Rheumatol* 2004;18:345–58. [PubMed: 15158745]
7. Pachman LM, Lipton R, Ramsey-Goldman R, Shamiyeh E, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. *Arthritis Rheum* 2005;53:166–72. [PubMed: 15818654]

- *8. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. *Lancet* 2008;371:2201–12. [PubMed: 18586175]
9. Bohan A, Peter JB. Polymyositis and dermatomyositis (two parts). *New Eng J Med* 1975;292:344–7. 403–7. [PubMed: 1090839]
10. Maillard SM, Jones R, Owens C, Pilkington C, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. *Rheumatology* 2004;43:603–8. [PubMed: 14983103]
11. Brown VE, Pilkington CA, Feldman BM, Davidson JE. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). *Rheumatology* 2006;45:990–3. [PubMed: 16467366]
- *12. Wedderburn LR, Varsani H, Li CK, Newton KR, et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. *Arthritis Rheum* 2007;57:1192–1201. [PubMed: 17907237]
13. Oddis CV, Rider LG, Reed AM, Ruperto N, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. *Arthritis Rheum* 2005;52:2607–15. [PubMed: 16142757]
14. Gregersen PK, Olsson LM. Recent advances in the genetics of autoimmune disease. *Annu Rev Immunol* 2009;27:363–91. [PubMed: 19302045]
15. Constantin T, Ponyi A, Orban I, Molnar K, et al. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary--clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. *Autoimmunity* 2006;39:223–32. [PubMed: 16769656]
16. Mamyrova G, O'Hanlon TP, Sillers L, Malley K, et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. *Arthritis Rheum* 2008;58:3941–50. [PubMed: 19035492]
17. Pachman LM, Jonasson O, Cannon RA, Friedman JM. Increased frequency of HLA-B8 in juvenile dermatomyositis. *Lancet* 1977;2:1238. [PubMed: 73944]
18. Reed AM, Pachman L, Ober C. Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501. *Human Immunology* 1991;32:235–40. [PubMed: 1783570]
- *19. Mamyrova G, O'Hanlon TP, Monroe JB, Carrick DM, et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. *Arthritis Rheum* 2006;54:3979–87. [PubMed: 17133612]
20. Wedderburn LR, McHugh NJ, Chinoy H, Cooper RG, et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. *Rheumatology* 2007;46:1786–91. [PubMed: 18003662]
21. Chinoy H, Payne D, Poulton K, Fertig N, et al. HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PMScl antibody positive idiopathic inflammatory myopathy. *Rheumatology*. 2009In press
22. Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. *Arthritis Rheum* 2000;43:2368–77. [PubMed: 11037898]
23. Chinoy H, Platt H, Lamb JA, Betteridge Z, et al. The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients. *Arthritis Rheum* 2008;58:3247–54. [PubMed: 18821667]
24. O'Hanlon TP, Rider LG, Schiffenbauer A, Targoff IN, et al. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. *Arthritis Rheum* 2008;58:3239–46. [PubMed: 18821675]
25. Wilson AG, Symons JA, McDowell TL, McDevitt HO, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. *Proc Natl Acad Sci U S A* 1997;94:3195–9. [PubMed: 9096369]
26. Chinoy H, Salway F, John S, Fertig N, et al. Tumour necrosis factor-alpha single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. *Rheumatology* 2007;46:1411–6. [PubMed: 17586554]

27. Manlhiot C, Liang L, Tran D, Bitnun A, et al. Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset. *Rheumatology (Oxford)* 2008;47:526–9. [PubMed: 18304939]
28. Pachman LM, Litt DL, Rowley AH, Hayford JR, et al. Lack of detection of enteroviral RNA or bacterial DNA in magnetic resonance imaging-directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis. *Arthritis and Rheumatism* 1995;38:1513–8. [PubMed: 7575702]
29. Mamyrova G, Rider LG, Haagensohn L, Wong S, et al. Parvovirus B19 and onset of juvenile dermatomyositis. *JAMA* 2005;294:2170–1. [PubMed: 16264157]
30. Vegosen LJ, Weinberg CR, O'Hanlon TP, Targoff IN, et al. Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. *Arthritis Rheum* 2007;56:2719–28. [PubMed: 17665425]
31. Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. *Rheum Dis Clin N Amer* 1997;23:619–55.
- *32. Gunawardena H, Betteridge Z, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. *Rheumatology* 2009;48:607–12. [PubMed: 19439503]
33. Feldman BM, Reichlin M, Laxer RM, Targoff IN, et al. Clinical significance of specific autoantibodies in juvenile dermatomyositis. *J Rheumatol* 1996;23:1794–7. [PubMed: 8895161]
34. O'Hanlon TP, Carrick DM, Targoff IN, Arnett FC, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. *Medicine (Baltimore)* 2006;85:111–27. [PubMed: 16609350]
35. Targoff IN, Mamyrova G, Trieu EP, Perurena O, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. *Arthritis Rheum* 2006;54:3682–9. [PubMed: 17075819]
36. Gunawardena H, Wedderburn LR, North J, Betteridge Z, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. *Rheumatology* 2008;47:324–8. [PubMed: 18238791]
37. Bingham A, Mamyrova G, Rother KI, Oral E, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. *Medicine (Baltimore)* 2008;87:70–86. [PubMed: 18344805]
38. Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. *Arthritis Rheum* 2009;60:1807–14. [PubMed: 19479859]
39. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. *J Exp Med* 2005;201:591–601. [PubMed: 15728237]
40. Howard OM, Dong HF, Yang D, Raben N, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. *J Exp Med* 2002;196:781–91. [PubMed: 12235211]
41. Eloranta ML, Helmers S, Barbasso, Ulfgren AK, Ronnblom L, et al. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. *Arthritis Rheum* 2007;56:3112–24. [PubMed: 17763410]
42. Tezak Z, Hoffman EP, Lutz JL, Fedczyna TO, et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. *J Immunol* 2002;168:4154–63. [PubMed: 11937576]
43. O'Connor KA, Abbott KA, Sabin B, Kuroda M, et al. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. *Clin Immunol* 2006;120:319–25. [PubMed: 16859997]
44. Miles L, Bove KE, Lovell D, Wargula JC, et al. Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. *Arthritis Rheum* 2007;57:1183–91. [PubMed: 17907236]
45. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. *Ann Neurol* 1990;27:343–56. [PubMed: 2353792]

46. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, et al. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. *Arthritis Rheum* 1997;40:865–74. [PubMed: 9153548]
47. Sallum AM, Marie SK, Wakamatsu A, Sachetti S, et al. Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis. *J Rheumatol* 2004;31:801–7. [PubMed: 15088312]
48. Fall N, Bove KE, Stringer K, Lovell DJ, et al. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. *Arthritis Rheum* 2005;52:3175–80. [PubMed: 16200621]
49. Nagaraju K, Rider LG, Fan C, Chen YW, et al. Endothelial cell activation and neovascularization are prominent in dermatomyositis. *J Autoimmune Dis* 2006;3:2. [PubMed: 16504012]
- *50. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. *Mol Med* 2007;13:59–68. [PubMed: 17515957]
- *51. de Padilla, CM Lopez; Vallejo, AN.; McNallan, KT.; Vehe, R., et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. *Arthritis Rheum* 2007;56:1658–68. [PubMed: 17469160]
52. De Padilla, CM Lopez; Vallejo, AN.; Lacomis, D.; McNallan, K., et al. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. *Arthritis Rheum* 2009;60:1160–72. [PubMed: 19333937]
53. Reed AM, McNallan K, Wettstein P, Vehe R, et al. Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis? *J Immunol* 2004;172:5041–6. [PubMed: 15067086]
54. Li CK, Varsani H, Holton JL, Gao B, et al. MHC Class I overexpression on muscles in early juvenile dermatomyositis. *J Rheumatol* 2004;31:605–9. [PubMed: 14994413]
- *55. Nagaraju K, Raben N, Loeffler L, Parker T, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. *Proc Natl Acad Sci U S A* 2000;97:9209–14. [PubMed: 10922072]
56. Salomonsson S, Grundtman C, Zhang SJ, Lanner JT, et al. Upregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle. *Muscle Nerve* 2009;39:674–82. [PubMed: 19229963]
57. Li C, Knopp P, Moncrieffe H. Over expression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. *Amer J Pathology*. 2009a; eIn press
- *58. Miller FW, Rider LG, Chung YL, Cooper R, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. *Rheumatology* 2001;40:1262–73. [PubMed: 11709610]
59. Ruperto N, Ravelli A, Murray KJ, Lovell DJ, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. *Rheumatology* 2003;42:1452–9. [PubMed: 12832713]
- *60. Ruperto N, Ravelli A, Pistorio A, Ferriani V, et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. *Arthritis Rheum* 2008;59:4–13. [PubMed: 18163404]
- *61. Rider LG, Giannini EH, Brunner HI, Ruperto N, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. *Arthritis Rheum* 2004;50:2281–90. [PubMed: 15248228]
62. Ruperto N, Woo P, Cuttica R. The validated PRINTO core set and definition of improvement for juvenile myositis. *Arthritis Rheum* 2004;50 (S):S534. al e
63. Ravelli A, Ruperto N, Trail L, Felici E, et al. Clinical assessment in juvenile dermatomyositis. *Autoimmunity* 2006;39:197–203. [PubMed: 16769653]

64. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, et al. The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. *Rheumatology* 2007;46:1606–11. [PubMed: 17890275]
65. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, et al. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. *Arthritis Rheum* 2008;59:214–21. [PubMed: 18240194]
66. Huber AM, Lachenbruch PA, Dugan EM, Miller FW, et al. Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats. *Arthritis Rheum* 2008;59:352–6. [PubMed: 18311761]
67. Dugan EM, Huber AM, Miller FW, Rider LG. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. *Dermatol Online J* 2009;15:1. [PubMed: 19336018]
68. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, et al. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. *Arthritis Rheum* 2003;49:7–15. [PubMed: 12579588]
69. Smith RL, Sundberg J, Shamiyah E, Dyer A, et al. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. *J Rheumatol* 2004;31:1644–9. [PubMed: 15290747]
70. Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, et al. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. *Arthritis Rheum* 2008;59:222–6. [PubMed: 18240180]
71. Carroll CL, Lang W, Snively B, Feldman SR, et al. Development and validation of the Dermatomyositis Skin Severity Index. *Br J Dermatol* 2008;158:345–50. [PubMed: 18067478]
72. Klein RQ, Bangert CA, Costner M, Connolly MK, et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. *Br J Dermatol* 2008;159:887–94. [PubMed: 18616782]
73. Apaz MT, Saad-Magalhaes C, Pistorio A, Ravelli A, et al. Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. *Arthritis Rheum* 2009;61:509–17. [PubMed: 19333974]
74. Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, et al. Damage Extent and Predictors in Adult and Juvenile Dermatomyositis and Polymyositis Using the Myositis Damage Index. *Arthritis Rheum*. 2009In press
75. Traill L, Ruperto N, Pilkington CA, et al. The long-term outcome of juvenile idiopathic inflammatory myopathies: A multicenter, multinational study of 557 patients. *Arthritis Rheum* 2007;52:S830.
76. Sanner H, Gran JT, Sjaastad I, Flato B. Organ damage and prognostic factors in juvenile dermatomyositis. *Ann Rheum Dis* 2009;68(Suppl):S500.
77. McCann LJ, Garay SM, Ryan MM, Harris R, et al. Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. *Rheumatology* 2007;46:1363–6. [PubMed: 17569746]
78. Coyle K, Rother KI, Weise M, Ahmed A, et al. Metabolic abnormalities and cardiovascular risk factors in children with myositis. *J Paediatrics*. 2009In press
79. Kimball AB, Summers RM, Turner M, Dugan EM, et al. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. *Arthritis Rheum* 2000;43:1866–73. [PubMed: 10943878]
80. Rider LG. Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. *Rheum Dis Clin North Am* 2002;28:935–77. [PubMed: 12506779]
81. Bilgic H, Ytterberg SR, McNallan KT, Wilson T, et al. IL-17 and IFN-regulated genes and chemokines as biomarkers of disease activity in inflammatory myopathies. *Arthritis Rheum* 2008;58:S922.
82. Zipitis CS, Baildam EM, Ramanan AV. Treatment approaches to juvenile dermatomyositis. *Expert Opin Pharmacother* 2004;5:1509–15. [PubMed: 15212601]
83. Maillard SM, Jones R, Owens CM, Pilkington C, et al. Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis. *Arthritis Rheum* 2005;53:558–64. [PubMed: 16082634]

84. Pilkington CA, Wedderburn LR. Paediatric idiopathic inflammatory muscle disease: recognition and management. *Drugs* 2005;65:1355–65. [PubMed: 15977968]
85. Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, et al. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. *Arthritis Rheum* 2009;60:1825–1830. [PubMed: 19479872]
86. Ramanan AV, Campbell-Webster N, Ota S, Parker S, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. *Arthritis Rheum* 2005;52:3570–8. [PubMed: 16255046]
87. Seshadri R, Feldman BM, Ilowite N, Cawkwell G, et al. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. *Arthritis Rheum* 2008;59:989–95. [PubMed: 18576304]
88. Riley P, Maillard SM, Wedderburn LR, Woo P, et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. *Rheumatology* 2004;43:491–6. [PubMed: 14722349]
89. Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. *Rheumatology* 2005;44:386–9. [PubMed: 15572389]
90. Rouster-Stevens KA, Pachman L. Mycophenolate mofetil in juvenile dermatomyositis. *Arthritis Rheum* 2006;54:S680.
91. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. *Lancet* 1999;353:1762–3. [PubMed: 10347992]
92. Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. *Clin Rheumatol* 2008;27:1469–71. [PubMed: 18716733]
93. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. *Arthritis Rheum* 2005;52:601–7. [PubMed: 15692974]
94. Cooper MA, Willingham DL, Brown DE, French AR, et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. *Arthritis Rheum* 2007;56:3107–11. [PubMed: 17763414]
95. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. *Arch Dermatol* 2007;143:763–7. [PubMed: 17576943]
96. Ram R, Ben-Bassat I, Shpilberg O, Polliack A, et al. The late adverse events of rituximab therapy--rare but there! *Leuk Lymphoma* 2009;50:1083–95. [PubMed: 19399690]
97. Riley P, McCann LJ, Maillard SM, Woo P, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. *Rheumatology* 2008;47:877–80. [PubMed: 18403404]
98. Miller ML, Smith R, Abbott KA. Use of Etanercept in chronic juvenile dermatomyositis. *Arthritis Rheum* 2002;44(supplement):S306. al e
99. Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. *Ann Rheum Dis* 2008;67:1670–7. [PubMed: 18272672]
100. Holzer U, van Royen-Kerkhof, van der Torre P, Tzaribachev N, et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. *Rheumatology*. 2009In press
101. Rider LG. The heterogeneity of juvenile myositis. *Autoimmun Rev* 2007;6:241–7. [PubMed: 17317616]

Wedderburn and Rider 2009 Table 1

Myositis specific autoantibodies (MSAs) and Myositis associated autoantibodies (MAAs) in patients with JDM

Autoantibody	Autoantigen target	Frequency in Caucasian patients [*] %	Clinical features and associations in JDM
MSAs			
Anti-ARS:	Aminoacyl-tRNA synthetases [*]	1-5	Typically associated with those with moderate to severe weakness, may have arthritis, mechanics hands, Raynaud's, fevers, interstitial lung disease
Anti-Jo-1	Histidyl-tRNA synthetase	2-5	
Anti-PL-12	Alanyl-tRNA synthetase	1-3	
Anti-PL-7	Threonyl-tRNA synthetase	<1	
Anti-EJ	Glycyl-tRNA synthetase	<1	
Anti-OJ	Isoleucyl-tRNA synthetase	<1	
Anti-KS	Asparagynyl-tRNA synthetase	NA	
Anti-Ha	Tyrosyl-tRNA synthetase	NA	
Anti-Zo	Phenylalanyl-tRNA synthetase	NA	
Other MSAs			
Anti-Mi-2	DNA Helicase	~5	Classical cutaneous JDM
Anti-SRP	Signal recognition particle	1-3	Associated with severe, refractory polymyositis
Recently-Identified Myositis Autoantibodies:			
Anti-p155/140 or gamma protein	Transcriptional intermediary factor (TIF)-1	23-29	More severe cutaneous involvement, generalized lipodystrophy
Anti-p140 (MJ)	Thought to be the MJ autoantigen, nuclear matrix protein NXP2	13-23	Associated with calcinosis, contractures
MAAs			
Anti-U1-RNP	U1 ribonucleoprotein (snRNP)	~6	Associated with sclerodermatous overlap features
Anti-U3-RNP	U3 ribonucleoprotein (fibrillarin)	~1	Associated with sclerodermatous overlap features
Anti-PM-Scl	Nucleolar multi-protein complex	5-7	Associated with sclerodermatous overlap features
Anti-Ro	52 or 60Kd ribonucleoproteins (hYRNA)	~2	
Anti-La	Ribonucleoprotein	~1	
Anti-Ku	p70/p80 heterodimer, DNA-associated proteins	~1	
Anti-Topo	DNA Topoisomerase 1	1	

based on data from references [20,24,32,35,36] [38] and [101].

* Frequencies quoted are from data in Caucasian patients; however frequencies vary considerably in different ethnicities. Notably certain autoantibodies which are higher in African American patients include anti-Jo1, anti-SRP, anti-Ro and anti-URNP [24]. NA- not available as data not yet reported in cohorts of JDM patients.

TABLE 2

Comparison of proposed sets of measures for disease activity in juvenile dermatomyositis, from two international collaborative efforts.

	IMACS	PRINTO
Target population	All IIM, including JDM	JDM
Domain		
Physician assessment	Physician global assessment of disease activity by visual analogue scale (VAS) or Likert scale	Physician global assessment of disease activity by visual analogue scale (VAS) or Likert scale
Patient/parent assessment	Patient/parent global assessment of disease activity using by visual analogue scale (VAS) or Likert scale	Patient/parent global assessment of overall well being using by visual analogue scale (VAS) or Likert scale
Muscle strength	MMT	MMT, CMAS
Functional ability	CHAQ or CMAS	CHAQ
Laboratory measurement	At least two of CK, LDH, aldolase, ALT, AST	Not included in the final core set, but recommended to be reported: CK, LDH, aldolase, ALT, AST
Global disease activity tool	Not included	DAS or MDAAT
Extra-muscular disease	MDAAT	Not included
Health-related QOL	Not included; measured separately	CHQ Physical Summary score

PRINTO, Paediatric Rheumatology International Myositis Assessment and Clinical Studies Group; IIM idiopathic inflammatory myopathies; JDM, juvenile dermatomyositis; VAS, visual analogue scale; PRINTO, Paediatric Rheumatology International Myositis Assessment and Clinical Studies Group; IMACS, MMT, manual muscle testing; CMAS, Childhood Myositis Assessment Scale; CHAQ, Childhood Health Assessment Questionnaire; CK, creatine kinase; LDH, lactate dehydrogenase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DAS, Disease Activity Score; MDAAT, Myositis Disease Activity Assessment Tool, which combines the MYOACT (Myositis extra-skeletal muscle disease activity assessment by VAS) and the MITAX (Myositis intention to treat activity index) tools; QOL, quality of life; CHQ, Child Health Questionnaire. Modified from references 58-62.

Table 3**Therapeutic Options for Juvenile Dermatomyositis*****First Line Therapies***

Prednisone 1-2 mg/kg/day po
 Intravenous Methylprednisolone 10-30 mg/kg/pulse
 Methotrexate 0.4 - 1 mg/kg/week, or 15 mg/m²
 Adjunctive therapies: Hydroxychloroquine 3 – 6 mg/kg/day po
 Physical therapy
 Photoprotective measures
 Topical therapies for skin rashes
 Calcium and vitamin D for bone protection

Second Line Therapies

Intravenous gammaglobulin 1- 2 gm/kg/month
 Cyclosporine 2.5 – 7.5 mg/kg/day po divided bid
 Azathioprine 3 -5 mg/kg/day
 Combinations of the above

Third Line Therapies

Cyclophosphamide 500-1250 mg/m²/month intravenous pulse
 Mycophenolate Mofetil 30-40 mg/kg/day po divided bid
 Tacrolimus 0.1-0.25 mg/kg/day po divided bid
 Rituximab
 Anti-tumor necrosis factor alpha agents
 Combinations of the above

* treatment of JDM, whereas second and third-line therapies are most often used in the Agents as first-line therapies are among those most often used in the initial treatment of refractory patients, patients considered to have severe features, or patients with unacceptable medication toxicities, that are supported by at least one publication in patients with JDM. The order in which therapies or combinations of therapies are used is not implied by the listing in this table.